Skip to main content
Medicines for Malaria Venture
Developing antimalarials to save lives
Main navigation
Our work
Go back
Our work
MMV's pipeline of antimalarial drugs
Global health and societal change
Go back
Global health and societal change
Sustainable Development Goals
Gender equity
Antimicrobial resistance
Antimalarial drugs for children
African manufacturing
Research and development
Go back
Research and development
Target Product & Candidate Profiles
Frontrunner templates
Access to medicines
Go back
Access to medicines
Product registration maps
Antimalarial drug toolkits
Partnering & opportunities
Go back
Partnering & opportunities
Global partner network
Go back
Global partner network
Endemic country partners
Business model
Intellectual property rights
Opportunities
Go back
Opportunities
Careers
Requests for information or proposals
Newsroom
Malaria
Go back
Malaria
Definitions and symptoms
Malaria facts and statistics
Lifecycle of malaria parasite
5 species of Plasmodium parasites
History of antimalarial drugs
Malaria guidelines
About us
Go back
About us
About us
Go back
About us
FAQs
Diversity, Equity & Inclusion
Policies
Funding & expenditure
Donors
People & governance
Go back
People & governance
Staff bios
Board of Directors
North America Inc. Board
Access and Product Management Advisory Committee
Expert Scientific Advisory Committee
Global Safety Board
MMVOpen
Go back
MMVOpen
Open compounds
Go back
Open compounds
Call for antimalarial compounds
Global health priority box
Pandemic Response Box
Open dose and PK prediction tool
Open source drug discovery programme
Go back
Open source drug discovery programme
Open data repository
MMVOpen team
What are you looking for?
Home
Newsroom
News and Resources Search
Synthetic antimalaria drug enters clinical trials
Synthetic antimalaria drug enters clinical trials
Synthetic antimalaria drug enters clinical trials
1 October 2004
Jane Bradbury